Rhythm releases positive Imcivree data for younger age group

ELENA BESSONOVA/iStock via Getty Images Rhythm Pharmaceuticals ( NASDAQ: RYTM ) has released positive data on Imcivree (setmelanotide) in children between the ages of two years and five years old, which could set the stage for expanding its indication. The drug is currently approved for chronic weight management.